Published: May 2023

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies.

Published: February 2023

This advisory introduces readers to Cannabidiol (CBD), how it is derived, how it differs from THC and other cannabinoids, the risks and harms of CBD use, and common misconceptions given its broad availability.

Published: February 2023

The N‑SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its territories, and D.C. The annual report presents findings on the general profile of substance use and mental health facilities, use of pharmacotherapies/medications, language assistance provided, and suicide prevention services.

Published: January 2022

This data visualization illustrates the correlation between alcohol use and other substance use to inform parents/guardians and communities.

Published: December 2021

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

Published: November 2021

This Advisory reviews the evidence on prescription stimulant misuse among youth and young adults. It establishes prescription stimulant misuse as a public health problem, identifies associated risk and protective factors, and provides programs and action steps for stakeholders to prevent misuse.

Published: October 2021

The goal of this guide is to review the literature on prevention of marijuana use among youth, distill the research into recommendations for practice, and provide examples of the ways these recommendations can be implemented.

Published: September 2021

This guide intends to educate clinicians and other stakeholders about the harms of using more than one substance and consideration for addressing concurrent substance use (CSU) and concurrent substance use disorders (CSUD).

Published: August 2021

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

Published: July 2021

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.